Capsule endoscopy is a useful diagnostic test for assessing active small-bowel Crohn’s disease in patients with suggestive clinical symptoms but normal imaging, an Australian study suggests.
The Melbourne researchers say their findings support the integration of panenteric Crohn’s capsule endoscopy into the diagnostic algorithm for patients with known or suspected disease, given the potential to achieve earlier diagnosis and classify more accurately active disease.
Their study involved 22 patients with established or suspected Crohn’s disease referred from two tertiary IBD centres between January 2021 and August 2022. Patients with abnormal magnetic resonance enterography were excluded from the study.
All patients had undergone an ileocolonoscopy within 12 months preceding capsule endoscopy, with no active colonic Crohn’s disease observed.
Only 21 patients were included in the final analysis due to one patient failing the capsule endoscopy procedure – which involved the PillCam Crohn’s capsule to the caecum with water plus simethicone (80 mg) – due to delayed capsule transit.
For the 48% of participants with suspected Crohn’s disease (median age 37.5, 60% female), the most common symptom was abdominal pain, while the 52% with a diagnosis (median age 52, 73% female) most commonly had diarrhoea.
An elevated FC (>50 μg/g) was the most frequent abnormal biomarker.
Findings published in JGH Open [link here] showed that 86% of the cohort had evidence of active small-bowel Crohn’s disease (LS > 135) based on endoscopy.
Of the 11 patients with a pre-existing diagnosis of Crohn’s disease, 82% had a change in Montreal classification, with all nine patients with known Crohn’s disease adding L4 disease to their pre- existing Montreal classification, the authors said.
Overall, 57% of patients were classified to L1 + L4 disease, 9.5% to L3 + L4 disease, and 9.5% to isolated L1 disease following capsule endoscopy.
At six months following the procedure, almost all patients (94%) had clinician-directed modification to their therapy. Of these patients, 94% received a course of corticosteroid (either budesonide or prednisolone), 39% started on a thiopurine, and 44% on a biologic agent (adalimumab, ustekinumab or infliximab).